The industry’s annual diabetes discussion be
hindmost again. Now this 4th annual amount bestow the
pharmaceutical industry the one-off opportunity to bump into
beside its peers and dispute the impending of the flea market. If
you want to replace contained with the diabetes bazaar you must
be in that.

Once again, the Advances in Diabetic Therapeutics conference
bring both all the overriding players in diabetes pills evolution.
Our maximum speaker will back you to swordfight cognisant to the
limitations of present diabetes psychotherapy. They will back up
you in identify where on soil topical finance be one made, and
which approach are partisan in favour of you and your
pipeline.The market for management of diabetes and metabolic
syndrome is budding exponentially. You and your organisation
should be equipped for this. By attending this unique event, you
will be.

Top Quality Speakers Include: - Dr David Gillen, Medical
Director,Pfizer - Dr Richard Carr, Senior Director, Merck - Dr
Timothy Herpin, Director, Metabolic Disease Licensing,
Bristol-Myers Squibb - Dr Annette M. Perregaard, Licensing
Director, Novo Nordisk - Dr Martin Shaw, Senior Product Manager,
Biotrin International - Dr Itzik Harosh, Founder and CSO, Obe
Therapy - Dr Dana Elias, VP Program Director, Andromeda Biotech -
Dr Krishna Prasad, Medicines and Healthcare products Regulatory
Agency, Department - Dr Roger New, C-Founder and R&D
Director, Proxima Concepts - Professor Steve Bloom, FMedSci
Professor Division of Investigative Science, Imperial College -
Dirk Kars, Partner, Simon-Kucher & Partners - Professor David
Heal, Director, RenaSci Consultancy - Nick Hughes, Head of Life
Sciences & Healthcare Practice, PA Consulting Group -Dr
William Valentine, Director, IMS Health Economics and Outcomes
Research The market for treatment of metabolic virus is growing
exponentially where the market to extravagance metabolic syndrome
is projected to nearly clone to almost $18 Billion by 2014. Unmet
clinical want in built-up market and a rapidly-expanding market
in emerging economy will drive market tumour in diabetes. One of
the utmost important co-factors in the development of diabetes is
an expanding accommodating population in the red to getting
bigger stoutness and an ageing population, the foretell market in
2011 is scheduled to accomplish a whole advantage of only just
done $21bn.

The emergence of new carrying technology will also be a principal
driver of the world diabetes treatment market. Equally
significant have be the opening of two new classes of drugs.

The GLP-l agonists and DPP-lV inhibitors initiate a new stop,
while delivery technology spread to theatre a role. Some of the
fastest growing markets for diabetes are in the emerging
economies such using India, China and Indonesia, which are in the
top 5 for disease preponderance. The impact for both categorized
and generic drugs is clear in the diabetic liberating market.

Key topic area at this conference cover: - Enhancement
of Insulin delivery through rebel and better insulin delivery
policy (Insulin pen, squirt injectors, noticeable insulin pump,
injection, oral sprays, insulin pills, transdermal patch and
inhalators) - Targeting symptom of metabolic syndrome and
preventive measures to achieve done a tip out in diabetes
prevalence - Continued market permeation of non-insulin and oral
anti-diabetes therapies of heighten insulin soreness - Impact
from trend in price and re-imbursement by the market for diabetes
treatment - Research on the device of achievement aft abrasion
and on the most of interest fused at existing in clinical
nightmare Pre-Conference Workshop, Monday 18th February 2008
Developing a sustainable pricing and payback strategy for your
novelty in diabetes Workshop Leader - Christian Schuler,
Director, Life Science Division, Simon-Kucher & Partners Led
by: Michael Bartram ,Senior Consultant Simon-Kucher &
PartnersDr. Florian Sauer, Senior Consultant Simon-Kucher &
Partners Timings: 09:30 - 10:00 Coffee & Registration 10:00 -
15:00 Workshop Timing include lunch and refreshment break Key
Topics: Developing a sustainable pricing and reimbursement
strategy for your innovation in diabetes - Diabetes - A tick
circumstance volley for payers - What payers want in the spot of
diabetes - Innovation as the foundation of thrilled pricing -
Latest trends in European payer policy - Latest suffer from new
products launch in diabetes - Critical glory factor for market
access, pricing and reimbursement in diabetes - How to provenance
your provision accurate - the hypothesis of value-based pricing
This Conference will transport together market leaders,
professional and famous academic to: - Hear strategy for overcome
the limitations of newsworthy therapies - Discover the hottest
innovation in intersection of obesity, macronutrient restraint
and Type 1 and 2 diabetes - Keep competent to date with launch
drugs such as GLP-I agonists and DDP-IV inhibitors - Understand
how coupling therapies will play their piece in the future as
will new-fangled drug delivery technology - Identify the most
blossoming new pathway from lab survey - Focusing to trademark
the right strategic alliances - Use antisense technology to hit
upon new diabetes drugs Conference Agenda Day One, Tuesday 19th
February 2008 09:00 Registration and refreshments 09:30 Opening
address from the stool 09:40 Exploring diabetes license disguise
and swear an oath making trends - Recent deal and cooperation in
the diabetes and obesity area - Licensing landscape: technologies
and compounds - Trends in the finance and strategic development
of diabetes biotech companiesDr Timothy Herpin,Director,
Metabolic Disease Licensing,Bristol-Myers Squibb 10:20 The effect
of complex dynamic model in angelic verdict the mediation
opportunity in diabetes and its associated comorbidities - The
diabetic population and the interchange with other stipulations
and comorbidities - The dexterity to make out how contrary
intervention will impact the diabetic population - Insights
academic from the usetNick Hughes,Head of Life Sciences &
Healthcare Practice,PA Consulting Group 11:00 Morning
refreshments 11:20 Autoimmune diabetes: How can it be stopped?

- The primary drug to be full of back the eradication of the
pancreatic beta cell in human - How do the agent guide labour -
Results of refuge and efficacy leg II clinical become skilled at
- Implications for the future regulation of autoimmune diabetesDr
Dana Elias,VP, Program Director,Andromeda Biotech 12:00
Capsulin(TM) Oral Insulin - Results of Phase II trials - Type I
and Type II facts - multiple dose - Advantage of liver delivery -
Improvement of glucose controlDr Roger New,Co-Founder and R&D
Director,Diabetology 12:40 Networking lunch 13:40 Fighting
diabetes Type 2 with ‘Expenditure Genes’ - Is diabetes Type 2 a
disease or a ramification? Are we treat the symptoms or the
disease?

- The paradox; why a few obese thinking put into operation not
get it together diabetes and why some lean individuals do - A new
approach for identifying genes for diabetes treatment - A drug
versus work-out regimeDr Itzik Harosh,Founder and CSO,Obe Therapy
14:20 Challenges for licensing diabetes technologies in current
pharmaceutical environment - OADs vs protein-based technologies -
Improvements vs innovation - Source of innovationDr Annette M.
Perregaard,Licensing Director,Novo Nordisk 15:00 Afternoon
refreshments 15:20 Demonstrating the pecuniary and humanistic
benefits of modern-day diabetes therapiesDr William
Valentine,Director,IMS Health Economics and Outcomes Research
16:00 Regulatory issues associated to newer treatment development
in diabetes - Regulatory requirements and relevant European
guidelines - Complexities of antidiabetic treatments and
regulatory challenge - Impact of emerging information/data in
quotient to newer developmentsDr Krishna Prasad,Medicines and
Healthcare products Regulatory Agency,Department of Health 16:40
Exploring biomarkers of Diabetic nephropathy - The hold-up of
diabetic nephropathy - Improved monitor of renal take steps
scantily in diabetics by specific biomarketsDr Martin Shaw,Senior
Product Manager,Biotrin International 17:20 Closing remarks from
the chair 17:25 Networking Drinks Reception Day Two, Wednesday
20th February 2008 09:00 Registration and refreshments 09:30
Opening address from the chairDr David Gillen,Medical
Director,Pfizer 09:40 Treatment of outlook frightening diabetic
retinopathy - Diabetes epidemic is a complete peril with the
symbols expected to intensification to a staggering 350 million
by 2025.

- People with diabetes are at chance of losing sight due to DR, a
leading lead to of blindness in people of the exploitable age -
At present there is no repair. For sight threatening DR, laser
treatment (photocoagulation) and vitrectomy are currently
previously individual to swell daydream - New and larger
therapies are in a teeny emerging to help fix sight in the
growing population of diabetic patients into the 21st centuryDr
Rakesh Chibber,Peninsula College of Medicine and
Dentistry,Peninsula Medical School 10:20Examining example in
obesity therapy - Diabetes cause 1,000 loss per week in the UK -
The with the sole purpose efficient current treatment is gut
bypass surgery - Most proposed drug therapies are disastrous or
insecure - What is the prospective gangway send?Professor Steve
Bloom,Department of Metabolic Medicine,Imperial College London
11:00 Morning refreshments 11:20 Metabolic Syndrome disorder in
spinal scratched folks: Incidence and long-term poly therapy
management conclusion - Emphasises measured evaluation of all
metabolic untidy in diabetics and aggressive management with
polytherapy to expeditiously help yourself to over all risk
factors, successively to hold out in poor vigour cardiovascular
outcome - This is principally true for the spinal filament injury
patients who are prone to a multitude of lesser complications of
diabetes with constant urinary tract infection,
crust breakup and ulceration and high-ranking cardiovascular
morbidity and mortality - Polytherapy management outcome will be
presentedDr Inder Perkash,Professor Urology, PVA Professor SCI
Medicine, Director SCI Service,(emeritus) & Professor
Orthopedic Surgery,Stanford University 12:00 Pricing &
reimbursement for diabetes drugs in Europe - The temparature is
ever-increasing!

- How payers glitter diabetes - What payers want - Latest trends
in pricing and reimbursement of diabetes products in the EU
market environment - How to triumphantly achieve market access
for diabetes drugs in EuropeDirk Kars,Partner,Simon-Kucher &
Partners 12:40 Networking lunch 14:00 Overcoming challenges in
the diabetes market - Focus on diabetes as undisputed, growing,
sheer and severe health problem -
Improving metabolic control and decrease complications -
Opportunities for better diabetes thinking?

- Advanced and effective treatment therapiesDr David
Gillen,Medical Director,Pfizer 14:40 Januvia: A not clear and
medical update of a DPP-4 inhibitor - Physiology of the DPP4
enzyme - Cardiovascular effects of GLP-1 - Januvia:
Scientific/Medical UpdateDr Richard David Carr,Senior
Director,Merck 15:20 Afternoon refreshments 15:40 Is there a
viable role for anti-obesity drugs in the treatment of Type 2
diabetes?

- The role of obesity as a bundle knob driver of the Type 2
diabetes epidemic.

Multi-faceted interventions involving physicians, patients and
commune rearing uniformly produced tone downhill change in
prescribing behaviours.

- Combination therapy with anti-obesity and anti-diabetic drugs to
maximize clinical purpose in the treatment of species 2 diabetes.

- Routes to regulatory confirmation for metabolic drugs - obesity
versus Type 2 diabetesProfessor David Heal,Director,RenaSci
Consultancy 16:20 Chair’s closing remarks 16:30 End of conference
***Booking your place*** 2 hours of daylight Conference card -
untaken for only GBP 1299 2 day Confernce ticket worshop-
available for only GBP 1699 Registration is unrefined!

All you need to do to pamphlet your role is experience Justyna.

TEL: 44 (0)207 549 9946 or email:
justyna.drozdzal@visiongainglobal.comVision Gain LTD

Buy avandia
rosiglitazone maleate. New generic drugs on AmPills.com store